Vanda Pharmaceuticals | VNDA - Despesa De Juros Sobre A Dívida





Despesa De Juros Sobre A Dívida Alterar Data
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.06B 44.38M 2026-09
Akebia Therapeutics 342.13M 7.53M 2026-09
Alnylam Pharmaceuticals USD -84.37M 166.42M 2026-09
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
AstraZeneca USD 371M 31M 2026-09
Bristol-Myers Squibb USD 403M 4M 2026-09
Eli Lilly USD 316M 201.3M 2026-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Halozyme Therapeutics USD 6.04M 457K 2026-09
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 20.41M 1.57M 2026-09
J&J USD 43M 25M 2026-03
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Merck USD 525M 46M 2026-06
Minerva Neurosciences USD 2.31M 60K 2024-06
Moderna USD 10.96B 527M 2026-06
Novartis USD 281M 8M 2025-09
Pfizer USD 662M 5M 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Puma Biotechnology USD 3.37M 11K 2024-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 222M 65M 2026-09
Takeda JPY 63.38B 466M 2026-09
Teva Pharmaceutical Industries USD 414M 219M 2026-09
Ultragenyx Pharmaceutical USD 20M 2M 2026-09
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Veracyte USD 2K 1000 2023-12